Researchers tested whether probucol, a retired cholesterol-lowering drug, could increase levels of apolipoprotein E (apoE) in the brain fluid of older adults at risk for Alzheimer's disease. ApoE is a crucial protein that helps protect brain cells and clear harmful deposits. The small study enrolled 23 cognitively healthy people over 55 and developed personalized dosing strategies since probucol absorption varies widely between individuals. Participants took their customized doses for 12 months while researchers monitored brain fluid levels of apoE and watched for side effects. This approach represents a novel strategy for Alzheimer's prevention using an existing medication.
